Relay Therapeutics (RLAY) Projected to Post Quarterly Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $6.08 million for the quarter.

Relay Therapeutics Stock Performance

Shares of NASDAQ:RLAY opened at $4.16 on Thursday. The stock has a market capitalization of $696.30 million, a price-to-earnings ratio of -1.59 and a beta of 1.61. Relay Therapeutics has a 1-year low of $3.50 and a 1-year high of $11.07. The company’s fifty day moving average is $4.40 and its two-hundred day moving average is $5.66.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, insider Peter Rahmer sold 32,156 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $4.15, for a total transaction of $133,447.40. Following the transaction, the insider now owns 357,507 shares of the company’s stock, valued at approximately $1,483,654.05. This trade represents a 8.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sanjiv Patel sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $5.00, for a total transaction of $500,000.00. Following the transaction, the chief executive officer now directly owns 574,548 shares in the company, valued at approximately $2,872,740. The trade was a 14.82 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 570,152 shares of company stock valued at $2,491,157. Company insiders own 4.32% of the company’s stock.

Wall Street Analyst Weigh In

RLAY has been the topic of a number of research reports. JMP Securities reissued a “market outperform” rating and set a $21.00 target price on shares of Relay Therapeutics in a report on Thursday, December 12th. Leerink Partners dropped their target price on shares of Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, December 4th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Relay Therapeutics in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.50.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.